Benicar blood pressure
Searched over 200M research papers
Summary
6 papers analyzed
These studies suggest that Olmesartan medoxomil (Benicar) effectively reduces blood pressure in various patient groups, including those with hypertension, type 2 diabetes, and elderly patients, and can be used alone or in combination with other antihypertensive agents.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Efficacy of Benicar (Olmesartan Medoxomil) in Blood Pressure Management
Introduction to Benicar and Hypertension
Benicar, known generically as olmesartan medoxomil, is an angiotensin II receptor blocker (ARB) used to manage hypertension. It works by inhibiting the action of angiotensin II, a hormone that causes blood vessels to constrict, thereby lowering blood pressure and improving blood flow .
24-Hour Blood Pressure Control with Olmesartan Medoxomil
Studies have shown that olmesartan medoxomil is effective in controlling blood pressure over a 24-hour period. In a study involving patients with hypertension and type 2 diabetes, olmesartan medoxomil, either alone or in combination with hydrochlorothiazide (HCTZ), significantly reduced mean 24-hour ambulatory systolic blood pressure (SBP) by 20.4 mmHg and diastolic blood pressure (DBP) by 11.1 mmHg. This reduction was consistent throughout the day and night, demonstrating the drug's efficacy in maintaining stable blood pressure levels over a full day.
Comparative Efficacy of Olmesartan Medoxomil
Olmesartan medoxomil has been compared to other ARBs such as losartan, valsartan, and irbesartan. In a randomized, parallel-group study, olmesartan medoxomil at a starting dose of 20 mg/day was found to be more effective in reducing blood pressure than losartan potassium (50 mg/day), valsartan (80 mg/day), and irbesartan (150 mg/day). The study highlighted that olmesartan medoxomil achieved higher goal rates for critical ambulatory blood pressure values, particularly in the last hours of the dosing interval, indicating its superior efficacy in maintaining blood pressure control throughout the day.
Efficacy in Elderly Patients
The efficacy of olmesartan medoxomil combined with HCTZ has also been evaluated in elderly patients with stage 1 and stage 2 hypertension or isolated systolic hypertension (ISH). In a study involving patients aged 65 years and older, the combination therapy significantly reduced mean 24-hour ambulatory blood pressure and seated cuff blood pressure (SeBP) from baseline. The majority of patients achieved the target blood pressure goals, demonstrating the regimen's effectiveness and safety in older populations.
Safety and Tolerability
Olmesartan medoxomil is generally well-tolerated with a low incidence of adverse events. In the study involving patients with hypertension and type 2 diabetes, only 34.9% of patients experienced treatment-emergent adverse events, and a mere 7.8% had drug-related adverse events. Similarly, in elderly patients, the incidence of treatment-emergent adverse events was low, with less than 3% reporting drug-related hypotension.
Conclusion
Olmesartan medoxomil (Benicar) is a highly effective antihypertensive agent that provides significant 24-hour blood pressure control. It outperforms other ARBs in reducing blood pressure and achieving target blood pressure goals, particularly in patients with essential hypertension and those with type 2 diabetes. Its efficacy extends to elderly patients, making it a versatile option for managing hypertension across different patient demographics. The drug is well-tolerated, with a low incidence of adverse events, further supporting its use as a reliable treatment for hypertension.
Sources and full results
Most relevant research papers on this topic
5
New ARB approved for hypertension by the FDA
5
0 Citations
2002
7
Tribenzor for hypertension.
7
0 Citations
2010